Evidence map›Paper›PMID 39636350›Full record

ArticleEJNMMI research2024

P2X

Jussi Lehto, Richard Aarnio, Jouni Tuisku, Marcus Sucksdorff, Esa Mikko Koivumäki, Marjo Nylund, Semi Helin, Johan Rajander, Jonathan Danon, Jayson Gilchrist and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jussi LehtoTurku PET Centre, Turku, Finland. juleht@utu.fi.ORCID http://orcid.org/0000-0002-2589-2549
Richard AarnioTurku PET Centre, Turku, Finland.
Jouni TuiskuTurku PET Centre, Turku, Finland.
Marcus SucksdorffTurku PET Centre, Turku, Finland.
Esa Mikko KoivumäkiTurku PET Centre, Turku, Finland.
Marjo NylundTurku PET Centre, Turku, Finland.
Semi HelinTurku PET Centre, Turku, Finland.
Johan RajanderTurku PET Centre, Turku, Finland.
Jonathan DanonSchool of Chemistry, The University of Sydney, Sydney, Australia.
Jayson GilchristSchool of Chemistry, The University of Sydney, Sydney, Australia.
Michael KassiouSchool of Chemistry, The University of Sydney, Sydney, Australia.
Vesa OikonenTurku PET Centre, Turku, Finland.
Laura AirasTurku PET Centre, Turku, Finland.

Funding

Jane ja Aatos Erkon Säätiö Jane ja Aatos Erkon SäätiöNational Multiple Sclerosis Society National Multiple Sclerosis SocietySigrid Juséliuksen Säätiö Sigrid Juséliuksen SäätiöState research funding of the Turku University Hospital expert responsibility area State research funding of the Turku University Hospital expert responsibility areaTerveyden Tutkimuksen Toimikunta 330902Terveyden Tutkimuksen Toimikunta 337530
6 · The paper itself

Abstract

backgroundPET imaging of activated microglia has improved our understanding of the pathology behind disability progression in MS, and pro-inflammatory microglia at 'smoldering' lesion rims have been implicated as drivers of disability progression. The P2X

resultsOverall, tracer uptake in the MS brain was not significantly higher compared to HCs. In the 3 mm perilesional rim of all T1 lesions, tracer binding was higher among relapsing patients compared to progressive patients. Tracer binding was higher in males compared to females. Disease duration correlated with tracer binding in the normal appearing white matter. Age correlated negatively with tracer binding in the perilesional rims.

conclusionsEven as binding estimates obtained with the dual-input model were consistent with the expected distribution of P2X

Indexed as

Kinetic modellingMicrogliaMultiple sclerosisPET

Identifiers

PMID39636350
PMCPMC11621262

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.